Investor Relations

FDA Accepts OPKO's New Drug Application for Rayaldee™ more »

OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults more »

OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources more »

OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition more »

Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put OPKO Health, Inc.'s financial performance into perspective.

  • Events

  • Stock Information

Ticker OPK Exchange NYSE
Last Price 16.65 Change 0.19 down
Open 16.78 Previous Close 16.84
Day High 16.90 Day Low 16.56
52-Week High 19.20 52-Week Low 8.02
Quotes delayed at least 20 minutes. Information provided by eSignal.